Aging Demographics Will Drive Tablo Home Dialysis Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

15 Aug 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$39.00

64.9% undervalued

15 Aug

US$13.67

47.2%

10.0%

Author's Valuation

US$39.0

64.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$39.0

64.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.73%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.42%

Calculation

US$40.18m

Earnings '28

48.30x

PE Ratio '28

US$1.94b

Market Cap '28

US$1.94b

Market Cap '28

39.03m

No. shares '28

US$49.72

Share Price '28

US$49.72 Share Price '28

Discounted to 2025 @ 8.43% p.a.

US$39.00

Fair Value '25